Subtype
Biliary Tract Carcinoma
CI-CAN-00001970Explore in graph →
238 active trials3 approved drugs29 evidence items
- NCIt
- C156781
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001970Explore in graph →
Clinical trials
823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (111)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 42 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07070700 | Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma(CASTLE-ZS-02) | recruiting | Phase 2 | 56 | Fudan UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT05265208 | Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer(SIROCHO) | recruiting | Phase 2 | 62 | Center Eugene MarquisOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07105852 | Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma | recruiting | Phase 2 | 59 | Sir Run Run Shaw HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07025174 | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer(SAIB) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | recruiting | Phase 2 | 51 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06208462 | Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06852287 | Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer(GOLD-HAIC) | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04954781 | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05010681 | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence(GOT) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05532059 | Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06607276 | Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06664021 | Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06749730 | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma | recruiting | Phase 2 | 63 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06721286 | Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Dec 18, 2025source: clinicaltrials